CYBA Antibody (C-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P13498 |
---|---|
Clone Names | 101008270 |
Gene ID | 1535 |
---|---|
Other Names | Cytochrome b-245 light chain, Cytochrome b(558) alpha chain, Cytochrome b558 subunit alpha, Neutrophil cytochrome b 22 kDa polypeptide, Superoxide-generating NADPH oxidase light chain subunit, p22 phagocyte B-cytochrome, p22-phox, p22phox, CYBA |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | CYBA (HGNC:2577) |
---|---|
Function | Critical component of the membrane-bound oxidase of phagocytes that generates superoxide. Associates with NOX3 to form a functional NADPH oxidase constitutively generating superoxide. |
Cellular Location | Cell membrane. Note=As unassembled monomer may localize to the endoplasmic reticulum {ECO:0000250|UniProtKB:Q61462} |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Cytochrome b is comprised of a light chain (alpha) and aheavy chain (beta). This gene encodes the light, alpha subunitwhich has been proposed as a primary component of the microbicidaloxidase system of phagocytes. Mutations in this gene are associatedwith autosomal recessive chronic granulomatous disease (CGD), thatis characterized by the failure of activated phagocytes to generatesuperoxide, which is important for the microbicidal activity ofthese cells.
References
Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Katakami, N., et al. Atherosclerosis 212(2):534-538(2010)Tu, Y.C., et al. Acta Pharmacol. Sin. 31(7):874-880(2010)Moreno, M.U., et al. Drug News Perspect. 23(5):316-324(2010)Cross, D.S., et al. BMC Genet. 11, 51 (2010) :
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.